Microbot Medical Secures Sanmina Manufacturing Deal to Boost LIBERTY System Capacity, Cut Costs
MBOT sits 22% above its 52-week low of $1.6.
Summary
Microbot Medical has partnered with Sanmina to expand manufacturing for its LIBERTY Endovascular Robotic System. This agreement directly addresses the strong commercial momentum and rising demand for LIBERTY, following recent market releases, new account wins, and regulatory approvals. The partnership is expected to significantly boost production capacity, improve operational efficiencies, and lower manufacturing costs, which should lead to expanded gross margins. This is a critical operational step for the company to scale and capitalize on its product's market traction.
At the time of this announcement, MBOT was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.6M. The 52-week trading range was $1.60 to $4.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.